Compound News and Research

RSS

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

26 Oct 2009

APC enzyme may be effective for treating amyotrophic lateral sclerosis

A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.

26 Oct 2009

Biomoda to complete Phase II clinical trial of Biomoda assay for lung cancer detection

Biomoda, Inc., a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer.

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.

23 Oct 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Update from Karo Bio for the period January-September

In an update of the project portfolio, Karo Bio announced, among other things, that the company, in accordance with earlier communicated plans, has submitted an IND application for eprotirome to the American Food and Drug Administration (FDA); that a candidate drug has been nominated within the ER-beta program; and that the company has decided not to initiate further in-house development of KB3305 for the treatment of type 2 diabetes.

22 Oct 2009

GeckoSystems to discuss its sensor fusion based vision system

GeckoSystems Intl. Corp. (http://www.geckosystems.com/) -- announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 attendees will be able to observe and discuss GeckoSystems' sensor fusion based vision system, the CompoundSensorArray™.

22 Oct 2009

Compound News and Research

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Innovative approach to build a new drug to treat a number of CNS diseases

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

APC enzyme may be effective for treating amyotrophic lateral sclerosis

Biomoda to complete Phase II clinical trial of Biomoda assay for lung cancer detection

Updated data on XL184 study in patients with glioblastoma multiforme presented

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

KemPharm commences KP106 Phase 1 clinical trial for ADHD

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Update from Karo Bio for the period January-September

GeckoSystems to discuss its sensor fusion based vision system

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

NicOx reports financial results for the first nine months of 2009

Exposure to stress hormones and chemicals while in the womb can affect male fertility

Oxygen Biotherapeutics announces its expanded product development plan

U.S. Pharmacopeial fellowships awarded to 6 students

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News